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approaches should be considered to prevent microemboli-
zation postprocedure.
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DISCUSSION
Dr Ralph Dilley (LaJolla, Calif). President Andros, members
and guests. The growing interest of using stents to treat carotid
atherosclerosis is now well documented, and the modality is being
used increasingly in many clinics and practices, often in patients
who are asymptomatic and not in high-risk categories.
Unfortunately, we are beginning to learn of a number of
potentially significant complications of carotid stenting, which
might limit the application of this intervention. For instance, a
number of recent reports have shown an increase in postprocedure
stroke risk in patients over age 80. The incidence in these reports
varies from 7% to 15%.
Second, almost all investigators agree it is important to use
protection devices to decrease the frequency of atheroemboli
during carotid stenting. These protection devices range from sim-
ple filters to the more complex flow reversal system as described by
Parodi, but skepticism remains about their efficacy in capturing
atherosclerotic particles.
In spite of these precautions, atheroemboli continue to occur
during carotid angioplasty and stenting, and now we learn from
this very nice presentation by Dr Rapp and his colleagues that
atheroembolic showers occur not only during the procedure but
continue at least up to 48 hours following the procedure when no
protection device is in place.
Using diffusion-weighted MRI, analyzed both in coronal and
axial planes, they demonstrated a 9% incidence of new lesions at 1
to 2 hours after the stent placement but also a highly significant
78% incidence at 48 hours. Most patients had multiple lesions,
most often in the treated carotid distribution. All patients in their
study had placement of a protection device during the interven-
tion, and plaque fragments were present in the 44 submitted for
analysis.
This is an excellent study and if you are concerned that these
microembolic showers, although asymptomatic at the time, may
ultimately cause problems, then the results of this study are indeed
sobering and prompt many questions about the role of carotid
stenting. I should hope the authors would comment on some of
these questions.
Were you able to correlate the incidence of new lesions with
the age of the patient? Is it likely that the embolic lesions, partic-
ularly those outside the carotid territory were related to arch
atherosclerosis with embolic debris caused by catheter manipula-
tion?
I noted that the evaluation of the arch was by MRI only in
about 80% of the cases, and I wonder if this technique is sensitive
enough to identify significant arch pathology, which if present,
might alter the treatment plan?
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Were you able to correlate the number of embolic lesions with
any preintervention characteristics of the carotid plaque? For in-
stance, how did patients with recurrent disease as an indication
compare with de novo disease, and did you attempt to characterize
the plaque by duplex as to its degree of instability or heterogeneity
versus a stable or homogeneous plaque?
Should the workup prior to carotid stenting include trans-
esophageal echo to exclude arch pathology or duplex to evaluate
plaque characteristics, the findings of which might rule out stent-
ing as an option?
Can you elaborate a little further on what the clinical signifi-
cance of these lesions is? If they are a precursor to a dementia
syndrome and continue to embolize up to 48 hours or more, they
are very significant and a deterrent to expanding the indications for
carotid stenting.
Finally, a number of your patients in the study were asymp-
tomatic, and can you justify treating asymptomatic patients with a
stent, particularly with the findings you report today?
Again, I enjoyed this presentation and congratulate the au-
thors on an excellent study.
Dr Joseph Rapp. Thank you, Ralph. Ralph was very kind to
not comment on the extremely rough draft that I sent him the first
time around.
So do we know the timing of these lesions and could it happen
that we are just missing it and they are embolizing at the end of the
procedure and not during the procedure? Transcranial Doppler
during the procedure I think is pretty well worked out, and I do
not really understand why we do not have good data postproce-
dure because these people are monitored during the procedure in
some of these studies. We do not do transcranial Doppler. Actually
we now have a machine and we are going to start doing it for
obvious reasons that I talked about. And so I don’t know actually
the timing. My actual suspicion is that there is a lot more emboli in
the postprocedure period than we appreciate, and I think we are
going to look at that and hopefully work that out.
Does it correlate with age or the heterogeneity/homogeneity
of the plaque? Well, I hate to admit to a group of vascular surgeons
but I do not believe in homogeneity or heterogeneity of the
plaque, so we do not get it. I never have been convinced that was
worthwhile, but I knowmany of you do not share that opinion and
so you are welcome to do that study and see. We looked at every
parameter other than that that we could think of—degree of
stenosis, length of the lesion. You know we have MRI. We look at
all these lesions, and we could find nothing that correlated. We
only had 3 or 4 recurrent lesions, so it really was not worth looking
at whether they were recurrent or not. The recurrent lesions do
actually shed particles, which I was interested to find out . . .
Unidentified speaker. . . . paper was appreciated very much.
It was beautifully presented with good data, as usual. I have two
questions and a couple of comments. You mentioned that we
“don’t get emboli with carotid endarterectomy.” In fact, have you
subjected a group of patients in your institution who have under-
gone carotid endarterectomy to the same rigorous examination
with DWI as you did those undergoing angioplasty? Certainly if
you do transcranial Doppler on people that undergo CEA you see
a lot of hits in those patients, you just do not see them for long
periods of time, and while this may have been studied, I am not
aware of any literature right now to show that there are lesions
DWI after CEA unless there is an obvious complication. I am just
wondering if you happened to look at it because I think you are in
an excellent position to do that and to compare it.
Dr Rapp. We have. We published that in the Journal of
Neuroradiology in I think 2000-2001, and there is one from the
neurosurgery group in Phoenix. We found one lesion in 25 and
they found no lesions in 27 in diffusion-weighted imaging, so they
are emboli. I misspoke. I said there were no emboli. There are no
diffusion-weighted lesions after endarterectomy.
Unidentified speaker. The second question has to do
with your anticoagulant and antiplatelet regimen periprocedure.
Would you tell us a little bit about how much heparin you use,
whether you use aspirin and Plavix, and when you start it and how
long you continue it?
Dr. Rapp. We keep the ACT greater than 300 during the
procedure and we continue heparin for 12 hours postop, and in the
paper, one of the other alternatives that I mention is that maybe
when you stop the heparin you are getting more emboli. We load
the patients with Plavix either by 3 days before or, rarely, we load
them the night before, depending on their proximity to us, etc. We
continue Plavix for 6 weeks. Dr Pann and I have looked at
antiplatelet agent anticoagulation in our rat model of emboli, and
I can tell you even big doses of heparin make not a wit of difference
in the incidence or the number of lesions that you get when you
embolize cholesterol crystals.
Unidentified speaker. That is exactly the point. It suggested
it is not platelet or thrombotic material that is embolizing; it is
really plaque embolization that is really critical.
Obviously papers like this, for those who are interested in
carotid endarterectomy, make our day, or at least seem to, and you
are presenting this to a group of people who are very receptive
obviously to the data that you are presenting. I would strongly
encourage you to present this again at the stroke meetings, the
American Heart Association, where you do have an eclectic audi-
ence of neurologists, neurosurgeons, vascular surgeons, etc, be-
cause they are the ones who need to hear this. There is a proposal
up right now as a tag onto the CREST trial to do neuropsychiatric
evaluations of patients in both the carotid endarterectomy as well
as in the stenting group to see whether or not there is a difference
in intellectual functioning and whether or not these DWI lesions in
fact will be forerunners of dementia. I think it is terribly important.
Whether it gets funded or not is another question. I enjoyed the
paper and congratulations.
Dr Rapp. Thank you, and, Wes, I am only trying to continue
the work that you started at the San Francisco VA.
Dr James Watson (Seattle, Wash). I, like you, do not believe
in intervening in carotid stenosis that is less than 80% unless they
are clearly symptomatic, so I would like to drill down a little more
on your definition of asymptomatic.
Before coming down here I was presented with about a 60%
carotid stenosis who had an asymptomatic Hollenhorst plaque
discovered on retinal examination. How would you manage that
patient? And as a follow-up question, what do you do with the
asymptomatic carotid stenosis with a shown stroke by CT that
shows up in your office and says they have no symptoms, but once
again has a 50% to 79% carotid stenosis? Do you treat those patients
as symptomatic or asymptomatic?
Dr Rapp. I think they are tough calls. Generally, we treat
them as asymptomatic. We treat them that we do not know when
the stroke occurred. We do not know when the Hollenhorst
plaque occurred, and they weathered the storm and they have done
well. As you know, if you have your clinical event, you are at your
highest risk of recurrent event at that time, and that risk actually
goes down and at 2 years joins the population with carotid stenosis
that has never had an event. I think if you do not know when the
event started, you are down here in this low-risk category and you
have a 60% stenosis and you are not going to do anything.
Unlike our colleagues, I just went to a (Fox-Hollow) event
and was told that we should be treating asymptomatic SFA steno-
ses, so I think there is a group of people out there who are truly
scary in their indications to do these things. As our cardiologists
have discovered that there is atherosclerosis outside the heart, this
is a problem. It is a real problem when you have one standard to do
interventions and the person down the hall has another.
Dr Jean-Pierre Becquemin (Paris, France). I really enjoyed
your paper because I think it brings new clues that thesemay not be
so innocuous that we all hoped for. I was interested to see that the
majority of events occurred later on, after deployment of the stent.
That means that you change stable plaque to unstable plaque. That
means that all the debris goes through the strut of the stents, and
my question is did you use different types of stent? Did you find a
difference between open-cell stents versus closed-cell stents?
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Maybe you saw this paper at the last June meeting in Philadelphia
from a Belgium group which showed that with a closed-cell stent,
there were less emboli than with an open stent. Do you have the
same experience?
Dr Rapp. I have no experience with that. What I am inter-
ested in actually is a covered stent and there is a study looking at
covered stents in the carotid. Now that study was stopped because
of their high rate of restenosis. I have the reference in my poring
through Pub-Med to do this paper. I think that is very interesting,
but I have no data on closed or open-cell stents.
Unidentified speaker. I enjoyed your paper very much. A
couple of questions. There is some evidence experimentally at least
that you can increase the number and size of emboli by using
Dextran. Have you considered that?
Dr. Rapp. Increase?
Unidentified speaker. Decrease, size and number, by giving
Dextran. The other question is, in light of all this then, should we
be treating these people for 3 or 4 months with high-dose statins
and antiplatelet therapy before we stent them?
Dr. Rapp.Two really great questions. I love Dextran. Using it
for years and then in the last few, I don’t know, maybe 3 or 4 years
collectively had two anaphylactic reactions to Dextran, my love of
Dextran has been tempered, but Dextran is a very good drug, and
there is a wonderful TCD paper showing that these postoperative
embolizations actually stop when they put on Dextran. I think
Dextran is exactly where we are going to go. I am concerned about
the anaphylactic reaction to it.
In terms of statins and pretreatment with statins, that is a great
idea. Certainly in our asymptomatic patients where it is unclear
there is a rush to treatment that may well be a wonderful thing to try.
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